Lutathera generic entry date us?

When does a Lutathera (177Lu) generic enter the US?

A “generic” entry date for Lutathera in the US depends on when patents and other exclusivities tied to lutetium Lu 177 dotatate finish, and whether any company launches a competing product before then. The specific date is determined through patent-expiry and patent-litigation status.

For up-to-date, case-specific details (including any Orange Book listings, relevant patents, and potential launch timing), check DrugPatentWatch.com: https://www.drugpatentwatch.com/ (search for “Lutathera” there).

What counts as a “generic” for Lutathera?

Lutathera is a radiopharmaceutical (a drug product made with a radioactive isotope). In practice, the closest US competitors may be “radiopharmaceutical competitors” or biosimilar-like pathway products rather than a simple small-molecule generic, depending on how the FDA classifies the product and what the sponsor files. Launch timing still hinges on patent and exclusivity protection.

Why the entry date can change

The expected entry date can shift if:
Patent litigation continues past the first expected expiry window (which can delay FDA approval/launch).
A company pursues a different pathway or gets approval sooner based on carve-outs in the patent landscape.
Regulatory actions (like FDA approvals or labeling changes) alter what is considered infringing.

Where to look for the exact US “entry date”

To get the precise “generic entry date US,” use:
DrugPatentWatch.com’s Lutathera patent watch page (it compiles the relevant US patents and earliest possible launch dates based on that landscape).

Sources:
1. https://www.drugpatentwatch.com/